Humasis Co

Humasis Co Tax Expense

The Income Tax Expense of Humasis Co (205470.KQ) as of Nov 10, 2026 is 523.58 M KRW. In the previous year, Income Tax Expense was -2.02 B KRW — a change of -125.94% (higher).

Tax Expense

523.58 MKRW

YoY

-125.94%

Last updated:

Income Tax Expense of Humasis Co is 2025 523.58 M KRW. Income Tax Expense of Humasis Co was 2024 -2.02 B KRW. It decreases by -125.94% higher compared to the previous year.

The Humasis Co Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2018
0.00 KRW
Jan 1, 2019
0.00 KRW
Jan 1, 2020
24.61 M KRW
Jan 1, 2021
45.52 B KRW
Jan 1, 2022
54.93 B KRW
Jan 1, 2023
-6.76 B KRW
Jan 1, 2024
-2.02 B KRW
Jan 1, 2025
523.58 M KRW
The Humasis Co Tax Expense history
YEARTax ExpenseYoY
523.58 MKRW-125.94%
-2.02 BKRW-70.12%
-6.76 BKRW-112.30%
54.93 BKRW+20.67%
45.52 BKRW+184,906.36%
24.61 MKRW—
0.00KRW—
0.00KRW-100.00%
3.28 BKRW-443.05%
-955.09 MKRW-4,151.10%
23.58 MKRW+601.18%
3.36 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Income Tax Expense of Humasis Co is 523.58 M KRW in 2025.

Income Tax Expense of Humasis Co changed from -2.02 B KRW to 523.58 M KRW, representing a -125.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Humasis Co

All Key Metrics — Humasis Co